Abstract：
BACKGROUND: Condoliase-induced chemonucleolysis is a less invasive treatment for lumbar disc herniation (LDH); however, its long-term clinical outcomes remain unclear. We investigated 2-year clinical outcomes and assess radiographs after chemonucleolysis with condoliase.
METHODS: We enrolled patients with LDH who received condoliase therapy, with a minimum follow-up period of two years. Sixty-seven patients (44 men, 23 women; mean age, 46.7 ± 18.0 years) were analyzed. Time-course changes in disc height, disc degeneration, and herniation size were assessed. For clinical outcomes assessment, visual analog scale (VAS) scores for leg and back pain and the Oswestry disability index (ODI) were obtained at baseline and the 3-month, 1-year, and 2-year follow-ups. We obtained a questionnaire from these patients at two years to assess satisfaction and recommendation. Condoliase therapy was considered to be effective in patients whose VAS score for leg pain improved by ≥ 50% at 2 years from baseline and who did not require surgery.
RESULTS: Condoliase therapy was effective in 51 patients (76.1%). Eight patients (11.9%) required surgery due to ineffectiveness of the therapy. Condoliase therapy was ineffective in five out of six patients with a history of discectomy. The ODI and VAS scores for leg and back pain significantly improved from three months to two years. Of the patients, 80% satisfied with their outcomes, and 85% recommended this therapy. Progression of disc degeneration was observed in 57.1% of patients at three months; however, 30% recovered to baseline at two years. The mean disc height decreased at three months, but recovered slightly at one year and remained stable until two years. No recurrent disc herniation was observed.
CONCLUSIONS: Chemonucleolysis with condoliase was effective in 78% of patients with LDH for 2 years. Chemonucleolysis-induced disc degeneration was slightly recovered and maintained for two years post-injection. This treatment resulted in high patient satisfaction and recommendations.
METHODS: We enrolled patients with LDH who received condoliase therapy, with a minimum follow-up period of two years. Sixty-seven patients (44 men, 23 women; mean age, 46.7 ± 18.0 years) were analyzed. Time-course changes in disc height, disc degeneration, and herniation size were assessed. For clinical outcomes assessment, visual analog scale (VAS) scores for leg and back pain and the Oswestry disability index (ODI) were obtained at baseline and the 3-month, 1-year, and 2-year follow-ups. We obtained a questionnaire from these patients at two years to assess satisfaction and recommendation. Condoliase therapy was considered to be effective in patients whose VAS score for leg pain improved by ≥ 50% at 2 years from baseline and who did not require surgery.
RESULTS: Condoliase therapy was effective in 51 patients (76.1%). Eight patients (11.9%) required surgery due to ineffectiveness of the therapy. Condoliase therapy was ineffective in five out of six patients with a history of discectomy. The ODI and VAS scores for leg and back pain significantly improved from three months to two years. Of the patients, 80% satisfied with their outcomes, and 85% recommended this therapy. Progression of disc degeneration was observed in 57.1% of patients at three months; however, 30% recovered to baseline at two years. The mean disc height decreased at three months, but recovered slightly at one year and remained stable until two years. No recurrent disc herniation was observed.
CONCLUSIONS: Chemonucleolysis with condoliase was effective in 78% of patients with LDH for 2 years. Chemonucleolysis-induced disc degeneration was slightly recovered and maintained for two years post-injection. This treatment resulted in high patient satisfaction and recommendations.
摘要：
背景：Condoliase诱导的化学溶解是腰椎间盘突出症（LDH）的一种侵入性较小的治疗方法；然而，其长期临床结局仍不清楚.我们调查了2年的临床结果，并评估了condoliase化学核溶解后的X线照片。
方法：我们招募了接受condoliase治疗的LDH患者，至少随访两年。67名患者（44名男性，23名妇女；平均年龄，46.7±18.0年）进行了分析。光盘高度的时程变化，椎间盘退变,并评估了疝的大小。对于临床结果评估，在基线和3个月时获得腿部和背部疼痛的视觉模拟量表（VAS）评分和Oswestry残疾指数（ODI），1年,和2年随访。我们在两年时从这些患者那里获得了一份问卷，以评估满意度和建议。认为Condoliase治疗对腿部疼痛的VAS评分在基线后2年改善≥50％且不需要手术的患者有效。
结果：Condoliase治疗对51例患者（76.1％）有效。由于治疗无效，八名患者（11.9％）需要手术。六分之五的有椎间盘切除术史的患者中，Condoliase治疗无效。从三个月到两年，腿部和背部疼痛的ODI和VAS评分显着改善。在患者中，80%的人对他们的结果满意。85%的人推荐这种疗法。在三个月时，57.1％的患者观察到椎间盘退变的进展；然而，30%在两年时恢复到基线。平均椎间盘高度在三个月时下降，但在一年时略有恢复，并保持稳定，直到两年。未观察到复发性椎间盘突出症。
结论：在2年内，78％的LDH患者中，用condoliase进行化学核溶解是有效的。注射后，化学核溶解诱导的椎间盘退变略有恢复并维持了两年。这种治疗导致了很高的患者满意度和建议。
方法：我们招募了接受condoliase治疗的LDH患者，至少随访两年。67名患者（44名男性，23名妇女；平均年龄，46.7±18.0年）进行了分析。光盘高度的时程变化，椎间盘退变,并评估了疝的大小。对于临床结果评估，在基线和3个月时获得腿部和背部疼痛的视觉模拟量表（VAS）评分和Oswestry残疾指数（ODI），1年,和2年随访。我们在两年时从这些患者那里获得了一份问卷，以评估满意度和建议。认为Condoliase治疗对腿部疼痛的VAS评分在基线后2年改善≥50％且不需要手术的患者有效。
结果：Condoliase治疗对51例患者（76.1％）有效。由于治疗无效，八名患者（11.9％）需要手术。六分之五的有椎间盘切除术史的患者中，Condoliase治疗无效。从三个月到两年，腿部和背部疼痛的ODI和VAS评分显着改善。在患者中，80%的人对他们的结果满意。85%的人推荐这种疗法。在三个月时，57.1％的患者观察到椎间盘退变的进展；然而，30%在两年时恢复到基线。平均椎间盘高度在三个月时下降，但在一年时略有恢复，并保持稳定，直到两年。未观察到复发性椎间盘突出症。
结论：在2年内，78％的LDH患者中，用condoliase进行化学核溶解是有效的。注射后，化学核溶解诱导的椎间盘退变略有恢复并维持了两年。这种治疗导致了很高的患者满意度和建议。
